Clinical Conditions

“The endocannabinoid system is intimately involved in tissue healing in the face of inflammatory conditions, correlating clinically with prevention and treatment of inflammation-mediated pain.” – Fine & Rosenfeld, 2013

The Endocannabinoid System

  • CB2 receptors are present in the human dorsal root ganglion (DRG) sensory neurons, mediating nociceptive pain2
  • Cannabinoid receptor agonists modulate nociceptive thresholds.
  • CBD is a positive allosteric modulator at α1 and α 1 β glycine receptors.
  • Influences opioid, 5HT3, and N-methyl-d-aspartate receptors responsible for pain modulation
  • Cannabidiol (CBD)
  • Not psychoactive
  • Used as anti-epileptic, anti-inflammatory, analgesic, anti-emetic, anxiolytic and anti-psychotic
  • Inhibits THC-induced adverse reactions (ie. Anxiety, psychosis, intoxication)
  • May inhibit tumor growth
  • Inhibits tumor necrosis factor-α and ID-1 gene expression in metastatic cancers
  • Multiple in vitro and in vivo studies showed CBD is a potent inhibitor of human breast cancer cell aggression
  • Neuroprotective

Pain Management

Cannabinoid receptor agonists modulate nociceptive thresholds. CBD is a positive allosteric modulator at α1 and α 1 β glycine receptors. Glycine acts as an inhibitory postsynaptic neurotransmitter in the dorsal horn of the spinal cord. Several randomized, double-blinded, placebo controlled studies demonstrate cannabinoids as effective analgesics. Secondary outcomes from additional high-quality studies support these findings. Additionally, CBC’s anti-inflammatory effects were superior to NSAID’s in animal studies.

This information is presented for educational purposes only. Ananda Hemp developed this information to provide an understanding of the potential applications of cannabinoids. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.